Jaguar Health, Inc. (JAGX)
- ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
Jaguar planning to begin commercial launch of FDA-approved Gelclair® prescription gel for oral mucositis (also called "chemo mouth") in Q3 2024 Company to feature "Make Cancer Less Shitty" patient advocacy program at ONS Congress SAN FRANCISCO, CA ...
- ACCESSWIRE
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management of oral mucositis, a common, painful, and debilitating cancer treatment-related side effect ...
- ACCESSWIRE
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Jaguar planning to begin commercial launch in Q3 2024 for Gelclair®, the company's third prescription product Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive ...
